Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.
Frequently asked questions
What sector does Oscotec Inc (039200) operate in?
Oscotec Inc belongs to the Healthcare sector and operates in the Pharmaceuticals industry.
What is Oscotec Inc (039200) current stock price?
As of the latest data, Oscotec Inc stock price is ₩38,300, with a previous close of ₩38,300.
What is Oscotec Inc (039200) current market capitalization?
Oscotec Inc market cap is approximately 1.08 trillion.
Does Oscotec Inc (039200) pay dividends?
No. Oscotec Inc does not pay a dividend.
What is Oscotec Inc (039200) beta (volatility) score?
Oscotec Inc has a beta of 0.772, indicating lower volatility than the overall market.
